Recent Updates
Recently added Catalysts
CLDX

Celldex Therapeutics to Participate in the Cantor Fitzgerald 2nd Annual Healthcare Conference

Key Takeaway: HAMPTON, N.J., July 07, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Tibor Keler, Ph.D., Executive Vice President and Chief Scientific Officer, will participate in a fireside chat at the Cantor Fitzgerald 2nd Annual Healthcare Conference

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+77%
120-day peak, hindsight
Typical move
6.2%
average across 6 past catalysts
Cash runway
~37 mo
Minimal dilution risk
Lead asset
barzolvolimab
Phase 3 · Chronic Inducible Urticaria

Full Press Release Details

HAMPTON, N.J., July 07, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Tibor Keler, Ph.D., Executive Vice President and Chief Scientific Officer, will participate in a fireside chat at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 12, 2016 at 9:00 a.m. EDT in New York.
The live webcast will be available on the “Events & Presentations” page of the “Investors & Media” section of the Celldex website. A replay will be available for seven days following the event.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
Last updated: Jul 7, 2016